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IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS: A REVIEW AND A PROPOSED ROLE 
FOR PATIENT-REPORTED OUTCOMES. 
Conor W. Grady (Sponsored by Charles C. Matouk). Department of Neurosurgery, Yale University, 
School of Medicine, New Haven, CT. 
 
Despite nearly five decades of experience treating idiopathic normal pressure hydrocephalus (iNPH), 
there is still no consensus amongst care providers as to how to reliably identify patients with suspected 
iNPH who will benefit from shunt surgery, or how to measure post-operative symptom improvement. We 
performed a selective review of the literature, focusing especially on the role of neuroimaging in aiding in 
the diagnosis of iNPH, and the various clinical scales that have historically been used to assess outcome. 
Further, we tested the hypothesis that patient-reported outcomes (PROs) will demonstrate effectiveness of 
shunt surgery for the relief of iNPH symptoms consistent with that demonstrated through the application 
of clinical scales. To do this, we performed a retrospective analysis of one provider’s experience treating 
patients with suspected iNPH, scoring outcomes based on patient-reported change in symptom severity. 
All patients treated for suspected iNPH between January 2012 and January 2014 with at least one month 
of follow-up and documented responses to direct questioning about pre- versus post-surgical symptom 
severity were included. Twenty-one patients were included in total. 100% of patients reported 
improvement in at least one of the three cardinal symptoms of gait disturbance, urinary incontinence, or 
cognitive impairment following shunt implantation. Gait, urinary, and cognitive symptoms individually 
improved 95%, 84%, and 89%, respectively. There was a significantly higher rate of improvement in any 
(i.e. at least one) symptom domain using PROs compared to historical data obtained through evaluation 
with clinical scales. There was no statistically significant difference between improvements in each 
individual symptom domain. PROs produce results that are largely consistent with data obtained by 
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Normal pressure hydrocephalus (NPH) was first described in the English clinical 
literature in 1965 as a syndrome characterized by gait disturbances, cognitive 
impairment, and urinary incontinence in the setting of ventriculomegaly and normal 
opening pressure on lumbar puncture (1,2). Standard treatment for the disorder is the 
surgical diversion of CSF though the implantation of a shunt. Early clinical series 
reported questionable outcomes and high complication rates in shunt surgery for patients 
with NPH (3,4); in the decades that have followed, numerous studies have attempted to 
predict which patients will respond to shunting, leading to a proliferation of clinical 
scoring systems and proposed treatment algorithms (4-8).  
  
NPH is categorized as either secondary or idiopathic. Secondary NPH has an identifiable 
etiology, such as subarachnoid hemorrhage or meningitis, while the etiology of idiopathic 
NPH remains unknown. The diagnosis of idiopathic NPH (iNPH) is complicated by the 
similarity of its clinical presentation to that of other neurological diseases typically 
affecting patients over 65, including Alzheimer’s dementia and Parkinson’s disease, 
which do not respond to CSF diversion procedures (9). Because of this, current 
guidelines recommend the categorization of patients into “probable”, “possible”, or 
“unlikely” iNPH based on clinical and radiological findings that have been associated 
with positive response to shunting (10,13). The diagnosis of iNPH is definitely made by 




Despite the diversity of inclusion criteria and metrics for evaluating outcomes used by 
different studies, recent systematic reviews indicate that more than 70% of patients who 
receive a shunt for the treatment of iNPH will experience lasting improvement of at least 
one of their symptoms (14). As such, though little is known about its pathophysiology 
and no high quality studies have assessed the efficacy of shunting versus conservative 
management (15), there is evidence that iNPH is a clinical entity with an effective 
treatment.  
 
In this thesis, I present a review of the current literature on iNPH, with an emphasis on 
the role of neuroimaging, patient outcomes, and the various outcome measures used. We 
additionally include an analysis of the experience in treating iNPH at Yale-New Haven 
Hostpial, examining outcomes assessed by patient-reported primary end-points. The 
primary goal of this analysis was to investigate whether, in the absence of consensus 
means of evaluating outcomes in iNPH, using patient-reported endpoints will lead to a 
significantly different rate of response compared to the most recent rates reported in the 
literature. The secondary goal of this analysis was to examine if there are any patient 
characteristics that correlate with response to shunting for iNPH as assessed by patient-
reported end-points. 
 
Review of the Literature 
Methods 
The review presented in this thesis is based on a selective review of the literature, 
including the most recent English-language guidelines (10-13), select review articles 
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published since 2001, and original literature retrieved by a search of PubMed. As there is 
no level 1 data on the treatment or diagnosis of NPH, all clinical data summarized are 
level 2 or 3. Level of evidence is determined using the system established in the most 
recent international guidelines (15). 
 
Epidemiology 
Little is known about the prevalence and incidence of iNPH, as reported figures vary 
widely. A door-to-door survey of 982 individuals older than 65 resulted in a reported 
prevalence of 0.41% (17). Examining neurosurgical referrals in a stable Norwegian 
population, prevalence appeared to be highly age dependent, ranging from 3/100,000 in 
those aged 50-59 to 181.7/100,000 in those 70-79 (18). This same study reported an 
overall incidence of 5.5/100,000. A random sampling of a Japanese population aged 65 
years or older found the prevalence of iNPH to be 1.4% as diagnosed by 
ventriculomegaly on neuroimaging and at least one element of the classical clinical triad 
of gait disturbance, cognitive impairment, or urinary incontinence (19). In a population of 
assisted-living and extended-care facility residents, incidence ranged from 9% to 14% 
(20). All of these studies acknowledged that their findings were highly dependent on the 
diagnostic criteria used. 
 
Another important consideration in the epidemiology of iNPH is its rate of comorbidity 
with other neurologic disease. In a study of 28 patients with iNPH diagnosed by clinical, 
radiological, and CSF dynamic criteria, 89% had pathologic findings consistent with 
some neurologic disease, and 78% had evidence of Alzheimer’s disease, cerebrovascular 
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disease, or both (21). Others have reported biopsy-confirmed Alzheimer’s disease in as 
many as 75% of patients undergoing shunt placement for treatment of iNPH (22). Such 
data are significant, as it has been hypothesized that patients with dementia not entirely 
attributable to iNPH may still experience resolution of gait and urinary symptoms 
following shunting (23). 
 
Pathophysiology 
The exact pathophysiological mechanism by which iNPH arises is unknown. The most 
common pathological findings in iNPH are evidence of Alzheimer’s disease and 
cerebrovascular disease; there are no pathologic findings specific to iNPH (13). 
Numerous etiologies have been proposed for iNPH, with the majority attributing the 
disease to a combination of periventricular ischemia and disturbed CSF fluid dynamics 
(24). Current hypotheses include mechanical compression of the brain parenchyma by 
dilated ventricles, accumulation of toxic metabolic products as a result of decreased CSF 




Since its discovery, multiple criteria have been proposed for the diagnosis of NPH, 
ranging from positive response to shunt placement (26) to the presence of only one of the 
classic triad of symptoms with radiologic confirmation of communicating hydrocephalus 
(27). Because of the absence of a consensus set of diagnostic criteria, a considerable 
amount of research has been devoted to determining which patients are most likely to 
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respond to shunting (4-8). The information provided by these studies has been 
synthesized into international guidelines, which recommend that patients be diagnosed 
with “probable”, “possible”, or “unlikely” hydrocephalus based on a combination of 
clinical and radiological findings associated with positive response to shunt placement 
(10,13). One set of guidelines still reserves a definitive diagnosis of iNPH for those who 
show improvement of symptoms with shunting (13). 
 
Clinical Features 
The full syndrome of gait disturbance, cognitive impairment, and urinary incontinence 
may be present in as few as 51% of patients with probable iNPH (28). At least one 
component of the triad, however, is essential to the diagnosis of the disease. 
 
Gait impairment is the most common presenting symptom, though it may be subtle early 
in the course of the disease. The gait disturbance seen in iNPH is characterized by 
imbalance, short steps, broad stance, difficulty turning, and outward rotation of the feet. It 
does not improve with visual or auditory cues, unlike a Parkinsonian gait. Apraxia is 
rarely a component of the gait disturbance typical of iNPH (29). Depending on the 
precise diagnostic criteria applied, between 94% and 100% of patients with iNPH will 
have gait disturbances (13). Both sets of English-language guidelines have prominent gait 
disturbance as an essential feature of probable iNPH (10,13). 
 
The cognitive dysfunction seen in iNPH is typically frontal-subcortical in nature. Its most 
prominent features are impaired executive function, impaired concentration and attention, 
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psychomotor slowing, and impaired working memory (23,30). Recall memory is 
typically preserved. Features of cortical dementia such as gross amnesia, disorientation, 
and aphasia are decreased relative to the cognitive impairment typical of Alzheimer’s 
disease (30). Cognitive impairment is seen in 78% to 98% of patients with iNPH (13). 
 
The urinary symptoms of iNPH range from increased urinary frequency to gross 
incontinence. The underlying cause of the urinary symptoms is detrusor hyperactivity 
resulting from a reduction of central inhibitory control (31). Patients typically progress 
from increased frequency, to urge incontinence, and finally to frank urinary incontinence. 
Of note, bowel incontinence is extremely rare in iNPH, and is likely indicative of 
progressive frontal lobe dysfunction rather than further loss of central control over 
sphincter function (23). 
 
Average CSF opening pressure in patients with iNPH is mildly elevated relative to 
healthy individuals (32), but by definition must be below either 18cm H2O or 20cm H2O, 
depending on the diagnostic criteria used (10,13). 
 
In the patient’s history, age greater than 65, insidious onset, and progression of symptoms 
are consistent with a diagnosis of iNPH (10). An identifiable etiology of the 




The Role of Neuroimaging 
Radiologic evidence of hydrocephalus is essential to the diagnosis of iNPH. 
Traditionally, an Evans index (33) greater than 0.3 on CT or MRI has been the standard 
for the diagnosis of ventricular enlargement (10). This, in combination with the absence 
of evidence of CSF flow obstruction, constitutes the minimum radiologic indication of 
iNPH. Beyond this, however, there is considerable debate as to what other neuroimaging 
findings might be of use in the diagnosis and evaluation of iNPH. In the sections that 
follow, I will discuss ways in which various imaging modalities have been used to assess 
patients with suspected iNPH and assess their role in clinical practice. 
 
Anatomic and Volumetric Studies 
Since the advent of modern neuroimaging, numerous studies have attempted to identify 
anatomical and volumetric findings on conventional CT and MRI that could serve as 
diagnostic or prognostic markers for iNPH. One of the earliest such studies, by Borgsen 
and Gjerris (34), interrogated the possible connection between the degree of ventricular 
dilation as measured by the Evans index, the size of cortical sulci, and the presence or 
absence of periventricular lucencies with outcome following shunting in patients with 
suspected NPH. Sixty-four patients with either iNPH or secondary NPH who met the 
criteria of 1) presenting with the full triad of cardinal symptoms 2) symptom duration of 
greater than three months and 3) CT-confirmed ventriculomegaly were treated with 
ventriculo-atrial shunts. Their outcomes were then correlated with their findings on CT. 
Ventricular size was not significantly associated with outcome, but both small cortical 
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sulci and the presence of periventricular lucencies were identified as predictors of 
positive response to shunting (34). 
 
In the decades since the publication of Borgsen’s and Gjerris’s work, the proliferation of 
low-powered studies proposing radiologic findings with either diagnostic or prognostic 
value in the evaluation of iNPH have resulted in an inconsistent body of literature. Some 
findings, such as hippocampal atrophy, have been demonstrated in patients with iNPH 
relative to healthy controls, but are also known radiologic features of other 
neurodegenerative diseases, and are therefore of limited diagnostic significance (35). 
Others, such as the periventricular lucencies identified by Borgsen and Gjerris, have 
failed to consistently demonstrate their proposed utility as predictors of outcome (36,37). 
Still others have been complicated by revision, such as the discovery that limited areas of 
focal sulcal dilation in the setting of generally small cortical sulci could be observed in 
patients ultimately diagnosed with shunt-responsive iNPH (38). As a result, though there 
are many radiologic findings generally believed to be useful in the diagnosis or 
evaluation of iNPH, there is presently no consensus to what extent or in what way these 
findings should influence clinical practice.  
 
Despite this, many recent studies continue to attempt to identify additional anatomical 
and volumetric markers in suspected iNPH. A recently investigated anatomic marker is 
the callosal angle, which is measured between the lateral ventricles in a coronal image 
taken through the posterior commissure and oriented perpendicular to the anterior 
commissure-posterior commissure plane. As a diagnostic aid, Ishii and colleagues 
 
 9 
demonstrated that patients with iNPH had significantly smaller callosal angles than either 
patients with Alzheimer’s dementia or healthy controls (39). Using a cutoff of 90°, they 
were able to distinguish iNPH from Alzheimer’s dementia with an accuracy, sensitivity, 
and specificity of 93%, 97%, and 88%, respectively. When they added to this the 
requirement of an Evans index of 0.3 or greater, their results improved to 96%, 97%, and 
94% (39). Virhammar, et al., investigated the callosal angle as a predictor of outcome 
following shunt surgery. Looking at 108 patients who received shunts for suspected 
iNPH, they found that patients with shunt-responsive iNPH had significantly smaller 
callosal angles than did patients whose symptoms did not respond to shunt surgery (59° 
versus 68°). Using ROC analysis, they determined an optimal cutoff of 63°, resulting in a 
sensitivity and specificity of 67% and 65%, respectively (40). 
 
Volumetric analyses have likewise yielded a variety of results. With respect to predicting 
surgical outcomes, one study of 26 patients with suspected iNPH failed to demonstrate 
any significant difference in mean ventricular volume ratio, mean brain volume ratio, 
mean pericerebral CSF volume ratio, or mean ventricular/pericerebral CSF volume ratio 
between shunt-responders and non-responders (41). Looking at compartmental variations 
in CSF volume, another group demonstrated that 11 patients with shunt-responsive iNPH 
had increased CSF volume in the lateral ventricles and Sylvian fissures, but decreased 
CSF volume in the superior convexity and medial subarachnoid spaces compared to 
patients with Alzheimer’s dementia and age-matched, healthy controls (38). Building on 
these findings, a multicenter, prospective study selected 100 patients for shunt surgery 
based on clinical presentation consistent with iNPH and MRI findings of tight superior 
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convexity and medial subarachnoid spaces with enlarged Sylvian fissures and 
ventriculomegaly, a constellation of imaging findings collectively referred to as 
Disproportionately Enlarged Subarachnoid-space Hydrocephalus (DESH). At one year 
following surgery, 69% of patients demonstrated improvement of 1 point or more on the 
modified Rankin Scale, and 89% had demonstrated improvement at some point during 
the year (42). 
 
In a prospective study of 43 patients with suspected iNPH, Lee and colleagues 
simultaneously investigated the connection between many of the proposed anatomic and 
volumetric markers of iNPH and response to CSF tap test. Frontal convexity narrowing, 
parietal convexity narrowing, empty sella, upward bowing of the corpus callosum, and 
narrowing of convexity with dilation of sylvian fissure CSF spaces (i.e. DESH) were all 
compared against patient response to the removal of 40ccs of CSF via lumbar puncture. 
Of these, both an empty sella and DESH were significantly linked to positive response to 
CSF tap test, with the presence of either of the two signs corresponding to a sensitivity, 
specificity, positive predictive value, and negative predictive value of 72.7, 81, 80, and 
73.9%, respectively (43). 
 
International guidelines have attempted to synthesize the literature on anatomic and 
volumetric findings in iNPH. The 2005 guidelines authored by the NPH independent 
study group listed callosal angle, temporal horn size, and periventricular lucencies as 
radiologic findings worth assessing when considering a diagnosis of iNPH (10).  More 
recently, the updated guidelines of the Japanese Neurosurgical Society, published in 
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English in 2012, did not list any anatomic findings, listing instead only those volumetric 
findings consistent with DESH as radiologic findings indicative of iNPH (13).  
 
Of note, though there are no anatomic or volumetric radiologic findings that can confirm 
a diagnosis of iNPH or predict a patient’s response to shunting, several studies have 
indicated that there are also no radiologic findings that should prevent a patient with 
suspected iNPH from being considered for shunt implantation. Specifically, deep white 
matter lesions representing hypertensive or lacunar infarcts are not predictive of a poor 
response to shunting, and therefore should not rule out a diagnosis of iNPH (44,60). 
 
Imaging of CSF Dynamics 
Abnormal CSF dynamics are believed to contribute to the pathogenesis of iNPH (24). As 
such, analysis of CSF flow using phase-contrast MRI has been investigated for potential 
diagnostic and prognostic information in the assessment of patients with suspected iNPH. 
Early studies were promising; a chart review of twenty patients, with eleven followed up 
to five years after shunt surgery, showed a significant correlation between increased 
aqueductal CSF flow void and good or excellent outcome (45). A later prospective study 
by the same author, however, failed to recreate this finding, while identifying CSF stroke 
volume through the cerebral aqueduct greater than 42μL as a predictor of shunt-
responsiveness (46).  
 
Subsequently, better-powered, better designed studies have failed to find significant 
differences in either CSF flow void intensity or CSF stroke volume between either shunt 
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responders and non-responders amongst patients with suspected iNPH, or between iNPH 
patients and patients with other forms of dementia. In a prospective trial of 49 patients 
shunted for suspected iNPH, CSF flow through the cerebral aqueduct did not 
significantly correlate with clinical outcome (47). Another study comparing patients with 
a clinical diagnosis of iNPH to patients with early Alzheimer’s dementia, patients with 
early vascular dementia, and healthy controls found that there was no difference in 
aqueductal stroke volume between the groups (48).  
 
More recent studies have continued to interrogate CSF stroke volume, while also 
investigating additional CSF dynamic parameters. In a retrospective study, Forner-Giner 
and colleagues stated that increased average CSF flow of 18.2mL/min and increased 
mean CSF stroke volume of 138.7μL were both 100% specific and 86% and 79% 
sensitive, respectively, at correctly identifying patients with shunt-responsive iNPH from 
patients with ischemic cerebrovascular disease (ICD) or healthy controls (49). It should 
be noted, though, that the cohorts in this study were unequal (61 healthy, 19 ICD, 24 
NPH) and were not age-matched.  
 
The diverse and occasionally contradictory nature of the results of these studies has been 
hypothesized to be the result of a high degree of variability in technique in image 
acquisition and data analysis between institutions (50). As such, both the diagnostic and 
prognostic value of phase-contrast MRI measurements of CSF fluid dynamics in the 





Functional imaging modalities measuring blood flow and metabolism can provide insight 
into regional patterns of activity or dysfunction within the brain. As abnormal cerebral 
blood flow (CBF) is thought to contribute to the pathogenesis of iNPH, a number of 
different types of functional imaging have been investigated for possible utility in the 
assessment of patients with iNPH. Below, we will discuss these various imaging methods 
and evaluate their role in guiding clinical decision making. 
 
Positron Emission Tomography (PET) 
One of the earliest studies examining the potential role of functional imaging in the 
treatment of iNPH investigated whether or not iNPH could be distinguished from 
Alzheimer’s dementia based on patterns of cortical metabolism. Three patients with 
NPH, seventeen with Alzheimer’s disease, and seven age-matched controls were 
compared to one another on the basis of fluorine-18-labeled fluorodeoxyglucose (18F-
FDG) utilization. Both the iNPH and Alzheimer’s groups showed reduced cortical 
metabolism relative to controls. The pattern of hypometabolism differed between the two 
groups, however; Alzheimer’s patients demonstrated a pattern of bitemporal 
hypometabolism, while NPH patients showed a global reduction in cortical glucose use 
(51).  
 
Subsequently, Momjian, Owler, and colleagues expanded on these findings by using 15O-
H2O PET to identify the thalami, basal ganglia, and periventricular regions as areas of 
decreased CBF in patients with iNPH relative to healthy controls (52,53). Klinge and 
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colleagues also demonstrated a correlation between decreased regional CBF in the medial 
frontal lobes and anterior medial temporal lobes as measured by 15O-H2O PET, and pre-
surgical symptom severity in patients with a clinical diagnosis of iNPH. In this same 
study, they also showed a significant difference between shunt responders and non-
responders with respect to increased medial frontal lobe CBF following shunt surgery, 
though there was no significant difference in regional CBF between these two groups’ 
pre-operative studies (54). 
 
Calcagni, et al., recently performed a prospective study of the change in regional cerebral 
metabolic rate of glucose (CMRglu), as measured by 18F-FDG utilization, following 
shunt surgery in 20 patients with clinically diagnosed iNPH. Following shunting, the 17 
patients who improved demonstrated globally increased CMRglu relative to their pre-
surgical studies. In contrast, the three non-responders only showed increased CMRglu in 
the left frontal cortex, left putamen, and right thalamus, respectively. Notably, there was 
no difference in CMRglu between shunt responders and non-responders on pre-operative 
exam. There was, however, a statistically significant correlation between the magnitude 
of increase in CMRglu and degree of clinical improvement between individual shunt-
responders’ pre- and post-operative studies (55). 
 
Though numerous studies have demonstrated post-operative changes in patterns of 
cerebral metabolism and blood flow, no studies to date have found any ability of PET to 
predict clinical outcome following shunt surgery in patients with suspected iNPH. 
Additionally, studies demonstrating findings of potentially diagnostic regional 
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hypometabolism or hypoperfusion have used small cohorts. Though studies utilizing PET 
offer a promising glimpse into possible mechanisms of pathogenesis in iNPH, they have 
done little to establish PET’s clinical utility.  
 
Single-Photon Emission CT (SPECT) 
Early studies attempting to correlate patterns of regional CBF visualized by SPECT with 
diagnosis or outcome following shunting in patients with suspected iNPH offered 
promising results. In a study of 22 patients who received shunts following a clinical 
diagnosis of iNPH, Graff-Radford and colleagues found that an anterior/posterior CBF 
ratio cutoff of 1.05 was able to correctly classify the outcome in 19 of the cases; all but 
one of the patients who did not respond to shunting had anterior/posterior CBF above 
1.05, while all but two of the patients who responded to shunting had ratios below this 
threshold (56). This same group subsequently recreated these findings, showing that 
increased anterior/posterior CBF ration correlated with increased likelihood of a non-
response to shunting in patients with suspected iNPH (57). 
 
In a study of 37 patients with suspected iNPH, Chang, et al., demonstrated decreased 
mean CBF relative to age-matched healthy controls. This same study showed that 
patients who responded to shunting, while still possessing lower mean CBF than controls, 
had higher CBF than patients with suspected iNPH who did not respond to shunting (58). 
 
More recent studies have failed to reproduce these promising initial results. A study of 84 
patients with iNPH as diagnosed by DESH criteria found three patterns of reduced 
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regional CBF relative to healthy controls. Specifically, 58% of patients showed anterior-
dominant reduction in CBF, 12% showed posterior-dominant reduction, and 30% had 
mixed or diffuse-type reduction. Though the finding of predominantly anterior reduction 
in CBF in the majority of patients would seem to support the earlier finding of a 
relatively lower anterior/posterior CBF ratio in shunt-responders, there was no significant 
difference in responsiveness to shunting between the three types, which responded at 
rates of 83, 90, and 84%, respectively (59). A similar pattern and patient distribution of 
anterior-, posterior- and mixed-type reduced CBF was seen in a more recent study, which 
also showed no link between the pattern of reduced CBF and outcome (60). 
 
While SPECT has consistently demonstrated patterns of reduced CBF in patients with 
suspected iNPH relative to healthy individuals, the largest and most recent studies 
investigating the utility of the modality as a prognostic or diagnostic tool have failed to 
show a significant link between SPECT findings and patient outcome.  
 
Dynamic Susceptibility Contrast MRI 
Relatively few studies have attempted to use MR perfusion studies to identify diagnostic 
or prognostic markers of use in the assessment of patients with suspected iNPH. The 
largest and most recent of these was a prospective study conducted by Zieglitz, et al., in 
which dynamic susceptibility contrast MRI findings in user-selected regions-of-interest 
were compared in 21 patients with the clinical diagnosis of iNPH and 16 age-matched 
healthy controls. All members of the iNPH cohort were then shunted, and pre- and post-
operative imaging studies of shunt responders and non-responders were compared. 
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Patients with iNPH demonstrated significantly reduced regional CBF in the basal medial 
frontal cortex, the hippocampus, the lentiform nuclei, and all regions of the 
periventricular white matter compared to healthy controls. With respect to outcomes, 
shunt responders demonstrated a greater reduction in CBF of the periventricular white 
matter compared to non-responders, which fit with the additional finding that the 
magnitude of reduction of CBF to the periventricular white matter seen on pre-operative 
studies was directly correlated with symptom severity, and patients with worse 
symptomatology at the time of shunting received more obvious benefit from CSF 
diversion. Non-responders had reduced CBF of the basal medial frontal cortex relative to 
shunt responders (61).  
 
Further study is needed to establish the clinical role for MR perfusion studies in the 
assessment or management of iNPH. Presently, however, it is a modality that potentially 
offers insight into the pathogenesis of iNPH while further elucidating the findings of 
other functional imaging studies. 
 
Functional Imaging: Conclusion 
In a 2001 review, Owler and Packard noted that measures of CBF had failed to improve 
either the diagnostic or prognostic accuracy of the assessment of patients with suspected 
iNPH, largely due to center-specific technical and methodological differences (62). More 
than a decade later, this is still the case. Though functional imaging continues to be a 






The clinical utility of diffusion MRI has been the focus of a number of studies in recent 
years. Studies attempting to identify diagnostic markers by diffusion tensor imaging 
(DTI) have produced especially consistent results. Kim and colleagues looked at 
differences between 16 patients with shunt-responsive iNPH relative to 10 patients with 
Alzheimer’s dementia, 10 patients with vascular dementia, and 20 healthy controls using 
region-of-interest-based DTI. The iNPH patients were found to have higher fractional 
anisotropy (FA) in the posterior limb of the internal capsule (PLIC) relative to the all 
other cohorts. Using ROC analysis to arrive at an optimal cutoff value of 0.613, the 
authors were able to identify iNPH relative to either healthy controls or other dementia 
patients with a sensitivity and specificity of 87.5% and 95.0%, respectively (63). Another 
recent study used DTI to compare a cohort of 24 patients with a clinical diagnosis of 
iNPH to 20 healthy controls, and also found significantly higher FA in the PLIC of iNPH 
patients (64). This study found a considerably more significant decrease in FA in the 
corpus callosum of iNPH patients relative to healthy controls, however, and was able to 
correlate lower FA in the corpus callosum with worse gait symptomatology at 
presentation. Both of these studies support an earlier finding by Hattingen, et al., that 
patients with iNPH have higher FA in the periventricular corticospinal tract, and lower 




Aside from these findings, other diagnostic markers of iNPH on DTI have been proposed, 
including fornix length (66) and specific patterns of intracranial mean diffusivity (67), 
but these have yet to be reproduced by other studies. 
 
Previous studies have reported that patients with NPH had increased apparent diffusion 
coefficient (ADC) in the periventricular white matter (68). In a study of 11 patients with a 
clinical diagnosis of iNPH, Corkill, et al., investigated the ability of periventricular white 
matter ADC to predict patients response to shunting. Patients who did not improve with 
shunting were found to have significantly higher periventricular white matter ADC when 
compared both to shunt-responsive iNPH patients and age-matched healthy controls (69). 
More recently, it has been demonstrated that increased changes in ADC with each cardiac 
cycle can be of use in distinguishing iNPH from both healthy controls and patients with 
Alzheimer’s and Parkinson’s diseases (70,71). 
 
Diffusion MRI may provide diagnostic markers, especially on DTI, though these findings 
need to be validated in larger studies. The ability of diffusion MRI to predict patient 
outcome to shunting in cases of suspected iNPH is difficult to assess given the limited 
number of studies investigating the topic. 
 
MR Spectroscopy 
MR spectroscopy (MRS) enables investigators to search for distinguishing patterns of 
regional metabolite concentration in the brains of patients with likely iNPH. One early 
study attempting to differentiate various dementia syndromes from on the grounds of MR 
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spectroscopic data found that, of the syndromes investigated, only iNPH had potential 
marker on MRS (72). This marker, an increased lactate/creatinine ratio in intraventricular 
CSF, was also identified in a small cohort study conducted by Kizu and colleagues (73). 
 
More recent studies have investigated the relative concentrations of various metabolites 
within the brain parenchyma. In a prospective study comparing 24 patients diagnosed 
with iNPH on the grounds of clinical presentation, radiographic findings, and positive tap 
test, 11 patients with other forms of dementia, and 20 healthy controls, both iNPH and 
otherwise demented patients had decreased N-acetyl Acetate(NAA)/creatinine and 
NAA/choline ratios in their white matter relative to the control group. No significant 
difference was seen between the iNPH and other demented patients, and no significant 
correlation was found between MRS findings and response to shunting within the iNPH 
cohort (74). A similar finding was reported by Lundin, et al., who discovered decreased 
NAA levels in the thalami of patients with a clinical diagnosis of iNPH compared to age-
matched healthy controls (75). It should be noted, however, that Lundin, et al. showed 
decrease NAA in the thalami; there was no difference in NAA concentration between 
iNPH patients and controls in any other regions examined, including those investigated 
by the earlier study. 
 
The clinical role of MRS is uncertain at this time. Though some patterns of metabolite 
concentration in both CSF and brain parenchyma seem to correlate with a diagnosis of 
iNPH, the studies demonstrating these are small, and their findings are not sufficiently 




Neuroimaging – Conclusion 
The role of various imaging modalities in the evaluation of patients with suspected iNPH 
is an ongoing area of significant investigation. Presently, no single imaging modality can 
provide clinicians with definitive diagnostic or prognostic information.  
 
Treatment 
The discovery of NPH was defined by improvement of patients’ dementia following the 
diversion of CSF through the surgical placement of a shunt (2). Presently, shunt surgery 
remains the mainstay of treatment for iNPH; some diagnostic criteria even require a 
response of a patient’s symptoms following shunt placement for the diagnosis of 
definitive iNPH to be made (13). 
 
In the late 1990s, endoscopic third ventriculostomy (ETV) was proposed as an alternative 
to shunt surgery for the treatment of iNPH (76).  One multicenter study showed outcomes 
equivalent to those seen in patients treated with shunt surgery, with 69% of patients 
treated with ETV showing some improvement at 24 months after surgery (77). 
Subsequent studies demonstrated similar outcomes, though improvement was most 
significant in younger patients and in those with increased resistance to ventricular CSF 
outflow (78,79). 
 
Two recent studies have examined the relative safety and effectiveness of shunt surgery 
and ETV in the treatment of iNPH. A robust, population-based study used a national 
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database of the ICD-9 discharge codes for ETV and shunt surgery in patients diagnosed 
with iNPH to investigate the perioperative mortality and complication rate for each 
procedure. The findings showed ETV to have a perioperative mortality rate of 3.2% and a 
complication rate of 17.9% compared to a mortality rate of 0.5% and a complication rate 
of 11.8% in shunt surgery (80). Additionally, a randomized, parallel, open-label trial 
showed superior outcomes in patients treated with shunt surgery versus those treated with 
ETV; 76.9% of patients treated with shunt surgery showed some improvement 12 months 
after their procedure compared to 50% of those who underwent ETV (81). These studies 
indicate that shunt surgery is presently a safer and more effective treatment than ETV for 
iNPH. 
 
The role of conservative management in patients with suspected iNPH has not been well 
characterized. There is currently a double-blind, randomized, controlled trial assessing 
conservative management versus shunt surgery underway, but it has yet to announce any 
findings (82). One systematic review of the literature showed that a small number of 
patients with suspected iNPH may improve without surgical treatment, but that more than 
half of patients showed measurable deterioration in at least one of their symptoms three 
months after initial evaluation (83). A recent retrospective review compared serial pre- 
and post-operative exams of patients who had waited at least six months for shunt surgery 
after receiving a clinical diagnosis of iNPH to similar exams of patients who had received 
shunt surgery within three months of receiving their diagnosis. The delayed shunting 
cohort experienced significant decline in all symptom categories accept for incontinence 
in the months prior to their surgery, and their post-operative improvement, while 
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significantly improved over their last pre-operative exam, was significantly worse than 
the outcomes in the more rapidly shunted cohort (105).  
 
Presently, shunt surgery remains the treatment of choice for patients with iNPH. Current 
trials comparing conservative management to shunting will have the dual benefit of 
revealing what role conservative management should play in the treatment of iNPH, as 
well as providing level 1 data on shunt surgery’s effectiveness as a treatment for the 
disorder. The limited data that is available indicates that earlier shunting in patients with 
suspected iNPH may prevent further progression of the patients symptoms. 
 
Outcomes – Challenges 
The response of gait, urinary, and cognitive symptoms to shunt surgery has been central 
to both the discovery and subsequent decades of diagnosis of NPH. Despite this, there is 
no consensus metric by which improvement in these symptoms following shunting is 
measured. Numerous studies either measuring outcomes or attempting to predict which 
patients are most likely to respond to shunting have used a vast number of different 
clinical scales to assess pre- and post-shunting symptom severity. These studies have also 
employed a variety of inclusion criteria as a result of the absence of a single diagnostic 
marker for iNPH other than response to shunting. As a result, comparing outcome 
measures across studies is complicated, requiring careful attention be paid to the clinical 
scales used in each study, the inclusion criteria employed by each study, and each study’s 




In the sections that follow, I will first describe some of the types of clinical scales 
encountered in the literature on iNPH. I will then discuss outcomes as reported in the 
literature. An accompanying evidentiary table will outline which scales were used by 
selected studies, each study’s inclusion criteria, and the criteria by which each study 
scored an outcome as a positive response to shunting. 
 
Outcomes – Scales and Rating Systems 
Ordinal Scales 
Ordinal scales, in which a patient’s symptoms are assigned a ranking according to their 
severity, were amongst the first rating systems used in the evaluation of treatment 
outcomes in iNPH. The symptom severity score in these scales is assigned based on the 
evaluating clinician’s assessment of the patient. One of the oldest rating systems still in 
use is the scale devised by Stein and Langfitt (3). This scale assigns a patient’s overall 
symptomatology a score between 0 (no deficit) and 4 (patient requires full custodial 
care). The clinical scale devised by Black (4) is similar to the Stein-Langfitt scale, as it 
scores the patient’s overall symptomatology without distinguishing between specific 
symptoms. Unlike the Stein-Langfitt scale, which enables the comparison of pre- and 
postsurgical scores, the Black scale directly rates a patient’s response to treatment; a 
grade of “poor”, “transient”, “fair”, “good”, or “excellent” is assigned based on the extent 





Ordinal scales that evaluate each symptom of iNPH separately have also been used 
(88,89,90,91,92,94).  Though the criteria for specific rankings of symptom severity differ 
from scale to scale, they all require individual scoring of at least gait disturbance, 
cognitive impairment, and urinary incontinence. These specific symptoms scores are then 
summed to provide a final iNPH score. As with the Stien-Langfitt, and Black scales, the 
symptom scores are determined by the judgment of the assessing physician. 
 
These scales are easy to employ and provide a general picture of the severity of a 
patient’s disease. They are widely used and are the most common outcome assessment 
tool encountered in the iNPH literature. A major disadvantage of these scales, however, is 
that they are supported by few objective measures and rely heavily on the assessing 
clinician’s judgment. To address this, the creators of one scale demonstrated significant 
interrater reliability (κ = 0.76 – 0.85) when comparing a small number of expert raters, 
though they cautioned that physicians less familiar with the treatment of iNPH would 
likely need additional training before employing their scale (94). As such, there are 
questions regarding the external validity of studies relying solely on ordinal scales to 
assess patient outcome (100).  
 
Improvement Indices 
To facilitate more direct assessment of outcomes, at least two different improvement 
indices have been proposed. Both begin with the scoring of either symptom severity or 
improvement on an ordinal scale. The Krauss Improvement Index (85) scores symptom 
improvement following shunting as 0 (no improvement), 1 (fair or good improvement), 
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or 2 (excellent improvement). The sum of these improvement scores is then divided by 
the two times the number of cardinal symptoms present prior to shunting. The end result 
is a number between 0 and 1, with 0 indicating no improvement in any symptom, and 1 
indicating excellent improvement in all symptoms. The NPH Recovery Rate, proposed by 
Kiefer, et al. (89), begins with the calculation of pre- and post-surgical ordinal scale 
ranking comprised of the sum of individual symptom scores. The NPH Recovery Rate is 
then calculated by subtracting the pre- and postsurgical ordinal scores, dividing the result 
by the presurgical score, and finally multiplying by ten - the larger the resulting NPH 
Recovery Rate, the more significant the improvement in the patient’s symptoms. 
 
Though these indices allow investigators to present the extent of a patient’s improvement 
with a single number, they do not provide any information that is not available prior to 
their calculation. In the case of the Krauss Improvement Index, outcome assessment can 
be made from the ordinal outcomes score assigned to each symptom. The difference 
between the pre- and postoperative ordinal scores in the numerator of the NPH Recovery 
Rate also allows for assessment of outcome without any further calculation. Additionally, 
these indices are limited by the reliability of the ordinal scales on which they are based. 
 
Validated Measures 
Other studies have assessed functional outcome or symptom severity using scales 
validated in diseases other than iNPH. The Barthels ADL Index and Modified Rankin 
Scale, both validated in the assessment of patients recovering from stroke, have been 
used to gauge overall functional status in patients with iNPH (28,86,87,93,99). Many 
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studies have evaluated the cognitive symptoms of iNPH using the Mini Mental State 
Exam, which was validated as a screening test for dementia in elderly patients 
(8,28,84,86,87,94,95). Numerous other psychometric tests have also been employed to 
allow for more precise identification of a patient’s cognitive dysfunction (12). Likewise, 
symptom specific tests for gait disturbance, such as the timed-up-and-go test, and urinary 
incontinence, such as the International Consultation on Incontinence Questionnaire – 
Short Form, have been used to evaluate the severity of those symptoms in iNPH 
(28,94,95). 
 
The use of validated tests addresses some of the limitations of iNPH-specific ordinal 
scales, such as uncertain external validity. It should be noted, however, that, as these 
scales were validated for the evaluation of diseases other than iNPH, their 
generalizability needs to be examined. For example, the frontal-subcortical dysfunction 
that is characteristic of the cognitive impairment in iNPH may not be detected by the 
Mini Mental State Exam, which was validated for the assessment of Alzheimer’s type, 
cortical dementia (101). 
 
Continuous Scales 
Recently, Hellstrom, et al. proposed a continuous iNPH rating scale based on a 
combination of ordinal and objective assessments of gait, neuropsychology, balance, and 
continence (102). Each symptom is scored from 0-100, with a score of 100 corresponding 
to the performance observed in an age-matched healthy population. The gait and 
neuropsychologic scores are the average of scores arising from both ordinal ranking and 
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objective assessment of symptom severity. For example, the final gait score is the 
average of three separate scores, each ranging from 0-100: an ordinal ranking, the 
number of steps required to walk 10m, and the time in seconds required to walk 10m. The 
balance and continence scores are provided by ordinal scales alone. The final iNPH score 
is the mean of the symptom scores, provided by the equation [(2xgait) + (neuropsch) + 
(balance) + (continence)]/5(or number of scores available). It should be noted that the 
gait score is given twice the weight of the other symptom scores, and that the 
denominator will change depending on the number of symptoms assessed at the time of 
testing. The creators of this scale further recommend a minimum improvement of 5 
points in the overall iNPH score as indicative of a response to shunting. 
 
This scale attempts to address some of the limitations inherent in simple ordinal scales 
through the inclusion of objective criteria for assessing gait and neuropsychologic 
functioning. Hellstrom and colleagues also assert that their scale is calibrated such that a 
score of 100 represents the performance of a healthy individual and lower scores provide 
an empiric basis for comparison of iNPH scores between patients – for example, a score 
of 50 corresponds to the 50th percentile of symptom severity. A significant limitation of 
this scale, however, is that it takes significantly longer to administer – 30 to 40 minutes 
total – compared to assessment with an ordinal scale. Additionally, two of its 
components, balance and continence, are rated by ordinal scales alone. Though these 
were shown to correlate significantly with the gait and neuropsychologic scores, they are 




Outcomes – Results 
Reported outcomes have varied widely. The most recent international guidelines quote an 
overall shunt response rate between 30-96% (12). In formulating their most recent 
guidelines, the Japanese Neurosurgical Society encountered 3-6 month improvement 
rates following shunting of 64-96%, 1-year improvement rates of 41-95%, and 3-5 year 
improvement rates of 28-91% in their review of the literature (13). A more recent review 
of the literature found that in all studies of iNPH outcomes published since 2006, 
improvement rates at 3 months, 1 year, and greater than 3 years were 81%, 82%, and 
73%, respectively (16). 
 
Improvement rates also vary between elements of the iNPH symptom triad. Gait is the 
most likely symptom to improve, with response rates in cognitive impairment and urinary 
incontinence both highly variable depending on the scales used to assess recovery. 
Overall response rates for the symptoms have been reported between 58-90%, 29-80%, 
and 20-82.5%, respectively (13). 
 
The most recent data indicate that many patients’ symptoms will demonstrate long lasting 
improvement following shunting for iNPH. A comparison of reviews of outcomes in 
patients who had shunts implanted for the treatment of iNPH demonstrates a trend toward 
better long term symptom improvement over the past 13 years; a 2001 review found that 
29% of patients experienced “prolonged or significant improvement” (103), while a 2013 
review reported that 73% of patients showed some improvement at 3 years or longer 
following surgery (16). One recent study investigating long-term symptom improvement 
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found that 90% of patients will report some improvement in at least one symptom at 5 
years following shunting, and 87% will continue to report improvement at 7 years (95).  
Another study reported an average Krauss Improvement Index of 0.70 at an average 
follow-up of 80.9 months after shunt surgery (97). 
 
Complication rates related to shunts in patients with iNPH have historically been high, 
with early series quoting complication rates as high as 35%, including an 8% mortality 
rate (4). A recent review showed that, since 2006, the overall complication rate of 21.4%, 
with a 0.2% mortality rate. The most common complication found by this review was 
need for later shunt revision, which accounted for 61% of all reported complications. The 
remaining complications were subdural hematoma, intracerebral hemorrhage, and shunt 
infection, which accounted for 20%, 1%, and 18% of all complications, respectively (16). 
 
Previous guidelines have emphasized the importance of weighing an individual’s risk-
benefit ratio when considering a patient with suspected iNPH for shunt surgery (10). To 
examine this, a computer model, using data acquired through a review of the literature 
current to 2005, ran a Monte Carlo simulation over a wide range of risk and benefit 
parameters. Their model case was a 65 year-old with suspected iNPH and mild to 
moderate Alzheimer’s type dementia. The simulation ran 1000 trials with 1000 patients 
each. The resulting data indicated that the complication rate would have to exceed 50% 
before liberal shunt implantation would cause more harm than benefit as measured by 




Review - Conclusion 
The comparison of studies investigating normal pressure hydrocephalus is complicated 
by an absence of both a consistently applied set of diagnostic criteria and a consensus 
means of measuring patient outcomes following shunt surgery. Despite this, the most 
recent data indicates that a majority of patients with iNPH will experience potentially 
long-term improvement of at least one aspect of their syndrome with shunt implantation. 
 
Though careful patient selection should remain at the center of all surgical decision-
making, the trends over the past decade with respect to shunt surgery in patients with 
suspected iNPH have been of decreasing risk and increasing effectiveness. It is likely that 
more patients with suspected iNPH would benefit from earlier shunting (104), and that 
even patients with significant medical and neurologic comorbidity would experience 
some benefit from CSF diversion (90,91,98,99). 
 
Patient-Reported Outcomes in iNPH 
Introduction 
In the absence of consensus diagnostic criteria or methods of measuring outcomes, the 
effectiveness of CSF diversion via surgical implantation of a shunt remains difficult to 
assess with certainty. Despite this, as demonstrated by the preceding review of the 
literature, the preponderance of evidence indicates that a significant number of patients 
will experience at least some improvement of their symptoms following shunt surgery. 
Though numerous clinical scoring systems have provided this heterogeneous body of 
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data, one significant end-point that is seldom reported is the patient-reported outcome 
(PRO).   
 
PROs are widely used in the clinical literature, 
often in conditions in which there is no easily 
quantified primary end-point (106). Given the 
lack of consensus metrics for measuring 
objective improvement in the iNPH, PROs 
could provide insight into the effectiveness of treatment for this disorder. 
 
This analysis examines the experience of patients treated for iNPH at our institution, and 
will report PROs pertaining to symptom improvement or deterioration following shunt 
surgery. The primary goal of this analysis is to compare outcomes provided by PROs 
with the most recent outcomes data reported by reviews of the literature employing 
traditional clinical scales such as those described in the preceding review (13,16). A 
secondary objective of this analysis will be to see if there are patient characteristics that 





Patient Characteristics at Presentation 
Average age 77.76 years 
Sex 
Female 9 (42.86%) 
Male 12 (57.14) 
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I conducted a retrospective evaluation of 
patients treated for iNPH with surgical 
implantation of a CSF diverting shunt 
between January 2012 and January 2014.  All 
patients’ surgeries were performed by the 
same provider. The diagnosis of iNPH was 
based on onset of disease in adulthood, 
progressive worsening of at least one of the 
three cardinal symptoms of gait disturbance, 
urinary incontinence, or cognitive impairment, 
and imaging confirmed communicating 
ventriculomegaly of unknown etiology. All 
patients with at least one month of follow-up 
and documented response to direct 
questioning about their pre- and post-
operative symptom severity were included in the study. In total, 21 patients were 
included in the final  




All patient data were obtained through a search of each patient’s electronic medical 
record. 
Symptoms at presentation 
Gait 21 (100) 
Urinary 19 (90.48) 
Cognitive 18 (85.71) 
Full triad 17 (80.95) 
Response to trial CSF diversion 
Improved 15 (71.43) 
Not improved 1 (4.76) 
Not performed 5 (23.81) 
Duration of symptoms 
< 12 months 9 (42.86) 
>12 months 12 (57.14) 
Cardiovascular comorbidities 
Hypertension 17 (80.95) 
Diabetes mellitus 4 (19.05) 




Hyperlipidemia 9 (42.86) 
Any 20 (95.24) 
Neurologic comorbidities 
Dementia 7 (33.33) 
Parkinson’s disease 4 (19.05) 
History of seizure 
disorder 
2 (9.52) 
Tremor 1 (4.76) 




Patients were evaluated in clinic by the same provider who would later perform shunt 
surgery. The clinical assessment of the physician with respect to severity of the three 
cardinal symptoms of gait disturbance, urinary incontinence, and cognitive impairment 
were recorded in each visit note. Additionally, the patient’s assessment of their 
symptomatology on direct questions about each symptom was recorded in each note. 
When present, the assessment of the patient’s primary health aide (e.g. spouse, visiting 
nurse) was also recorded. For the purposes of this analysis, a patient was considered to 
have a symptom at presentation if they endorsed progression of a cardinal symptom over 
time to the point where it had impacted their quality of life.  
 
Each patient underwent implantation of a right ventriculoperitoneal shunt using a 
MIETHKE proGAV adjustable, gravitational shunt system. The hospital course and 30-
day post-operative period of each patient were assessed for complications. Major 
complications were considered to be those that led to reoperation, hospital readmission, 
or deficit which would potentially negate any positive impact conferred by shunting at 
last follow-up. Minor complications included transient deficits and over- or under-
drainage from the shunt system correctable by adjustment of the shunt’s settings. 
 
At follow-up, all patients were directly asked to assess their current symptom severity 
relative to their pre-operative condition. Again, when applicable, the assessments of 
primary health aides were also recorded. In cases where both the patient’s and a health 
aide’s assessments were available, a patient was only scored as improved if both the 
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patient and the aide considered the patient improved post-operatively. For the purposes of 
this analysis, only patients who continued to self-report improvement in a symptom 
domain at their last follow-up were scored as improved. 
 
Based on the pattern of response, patients were divided into a complete-response cohort, 
for whom all symptom domains were improved by PROs at last follow-up, and an 
incomplete-response cohort. Significant difference in categorical data between the 
complete-response cohort and the incomplete-response cohort was examined using a two-
tailed Fisher’s exact test. As an F-test did not reveal significant difference in variance 
between the two cohorts, significant difference in continuous data was examined using a 
standard independent-samples t-test. Significant difference in the rate of response 
between symptoms was also investigated using a two-tailed Fisher’s exact test.  
 
Estimates for frequency of response to shunting reported in the most recent systematic 
review available for each symptom (13,16) were chosen to represent historical outcomes 
as measured by traditional clinical scales. Comparison of our cohort data and this 
historical data was performed using chi-squared analysis. 
 
3.3 Results 
All patients reported improvement in at least one symptom domain at last follow-up, and 
all but five patients reported improvement in all three symptom domains. Of the five 
patients who experienced no improvement or worsening of at least one patient domain, 
one patient experienced a worsening of their gait disturbance, one patient experienced no 
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change in their cognitive impairment, two patients experienced no improvement in their 
urinary incontinence, and one patient failed to respond in both the urinary and cognitive 







There was not a statistically significant difference in response to shunting between 
patterns of symptomatology at patient presentation.  
 
A comparison of the complete-response cohort to the incomplete-response cohort can be 
found in Table 3.  
  
Table 2 
Response by Symptoms 
 Present pre-operatively Improved at last follow-up 
Symptom   
Gait 21 20 (95.24%) 
Urinary 19 16 (84.21) 
Cognitive 18 16 (88.89) 





Patient Characteristics by Complete or Incomplete Response to Shunting 
 Complete Response (n = 16) Incomplete Response (n = 5) 
Average Age* 76 83.4 
Sex 
Female 7 (43.75%) 2 (40%) 
Male 9 (56.25) 3 (60) 
Symptoms at presentation 
Gait 16 (100) 5 (100) 
Urinary 15 (93.75) 4 (80) 
Cognitive 13 (81.25) 5 (100) 
Response to trial CSF Diversion 
Improved 11 (68.75) 4 (80) 
Not improved 1 (6.25) 0 (0) 
Not performed 4 (25) 1 (20) 
Duration of symptoms 
< 12 months 6 (37.5) 3 (60) 
> 12 months 10 (62.5) 4 (40) 
Cardiovascular comorbidities 
Hypertension 13 (81.25) 4 (80) 
Diabetes mellitus 3 (18.75) 1 (20) 
Coronary artery disease 4 (25) 2 (40) 
Peripheral vascular 
disease 
1 (12.5) 0 (0) 
Hyperlipidemia 7 (43.75) 2 (40) 
Any 15 (93.75) 5 (100) 
Neurologic comorbidities 
Dementia 5 (31.25) 2 (40) 
Parkinson’s disease* 1 (6.25) 3 (60) 
Any 5 (31.25) 4 (80) 
Complications 
Major 2 (12.5) 1 (20) 
Minor 4 (25) 1 (20) 
Total  6(37.5) 2 (40) 






The incomplete-response cohort demonstrated significantly higher average age and 
prevalence of Parkinson’s disease than the complete-response cohort. No other 
significant differences in patient characteristics were demonstrated. With respect to rate 
of improvement in any symptom domain, a significant difference was seen between our 
PROs and historical outcomes based on clinical scales. Otherwise, no significant 
difference was found between our PROs and clinically assessed historical data. These 







Patient Selection Rationale and Patient Characteristics 
As there is no consensus means of securing a diagnosis of iNPH except for a witnessed 
response to shunt implantation, and as current evidence suggests that more patients may 
benefit from earlier shunting, we applied a liberal set of diagnostic criteria, requiring only 
onset of disease in adulthood, gradual worsening of one of the cardinal symptoms of 
iNPH, and ventriculomegaly of unknown etiology on neuroimaging. Despite this, our 
patient population had a higher prevalence of the full clinical triad than what has been 
reported in previous reviews (10, 13), and most met the criteria for a diagnosis of 
“probable iNPH” as outlined by Mori et al (13). 
Table 4 
Response Compared to Historical Data 
 % improved - PRO % improved - historical 
Symptom   
Gait 95.24 90 
Urinary 84.21 82.5 
Cognitive 88.89 80 
Any* 100 82 




This inconsistency between our lenient diagnostic criteria and our patient population is 
likely a result of bias introduced by the referral pattern of our clinic. It is possible that 
referring physicians did not suspect iNPH until many features of the disease were present. 
 
Though the rate of cardiovascular comorbidity was very high in our patient population, 
each disease-specific prevalence was not significantly higher than those demonstrated in 
age-matched population studies (107). This was not the case with neurologic 
comorbidities; the rates of dementia and Parkinson’s disease in our patient population 
were both approximately five-times greater than those reported for age-matched cohorts 
in large epidemiologic studies (108,109). These higher rates of neurologic comorbidity 
may be consistent with previously reported findings of extremely high rates of 
histopathologic evidence of neurodegenerative disease in patients with iNPH (21,22). 
 
Our patient population largely resembled the population of previous studies of iNPH in 
so far as they were elderly, gait was the most common symptom at presentation, and the 
neurologic disease burden was higher than that seen in the general population. It differed 
from previous iNPH study populations primarily in the frequency with which patients 





Comparison of Patient-Reported Outcomes to Historical Outcomes 
The PROs of this study were responses to a direct question asking the patient to compare 
their pre- and post-surgical symptom severity. In total, our findings are largely consistent 
with the historical clinical outcomes data; gait is the most likely symptom to show 
improvement, while cognitive and urinary symptoms are less responsive. Overall, all 
three symptoms domains demonstrated a response rate greater than 80% following 
implantation of a shunt.  
 
Two factors likely contributed to the significant difference in the rate of improvement in 
any (i.e. at least one) symptom domain demonstrated between this study and the 
historical data despite the absence of a significant difference in the rate of response for 
each individual symptom domain. First, it is possible that the insignificant differences in 
the rate of improvement observed between our data and the historical data with respect to 
each symptom reached significance when the datasets were combined to tabulate the 
outcome in the “any” domain. It is also likely that difference in method between the 
reviews from which the historical data was collected contributed to this result (13,16). 
Unfortunately, there has not been a single systematic review examining the response of 
all individual symptoms, which necessitated the compiling of this data from various 
sources. Likewise, there has been no review on the rate of response to shunting by 
symptoms at presentation; as such, there was no reliable data available on the historical 
rate of improvement in the symptoms of patients presenting with the full triad. This 





In the absence of a gold-standard metric for assessing outcomes in iNPH, this study 
demonstrates that PROs obtained from a typical iNPH patient population produce largely 
similar data on the effectiveness of shunting when compared to the various clinical scales 
that have been historically employed in the literature. The differences that are observed 
demonstrate higher rates of symptom improvement, though this is only significant when 
outcomes from all symptom domains are summed. A larger, prospective study comparing 
PROs and assessment using a clinical scale would be useful in determining if PROs 
actually lead to higher reported rates of symptom improvement. If such a difference were 
to be confirmed, further study would be needed to determine the reasons underlying the 
patient perception of improvement in the absence of improvement on clinical grading 
scales. 
 
Comparison of Complete-Response Cohort and Incomplete-Response Cohort 
Significant differences in average age and the prevalence of Parkinson’s disease were 
demonstrated between the complete-response cohort and the incomplete-response cohort. 
The average age of patients in the incomplete-response cohort was more than seven years 
greater than the average age in the complete-response cohort, and of the four patients in 
our total patient population with Parkinson’s disease, three failed to achieve improvement 
in all symptom domains. Of note, the symptoms that did not improve in the patients with 
Parkinson’s disease, urinary incontinence and cognitive impairment, are also known to 
occur in the course of that illness. As such, it is possible that the lack of response to 
shunting in these patients is the result of their underlying comorbid condition. 
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Significantly, however, these patients still reported experiencing improvement of their 
gait dysfunction. This supports previously reported data that even patients with suspected 
iNPH who also have significant neurologic comorbidity can derive some benefit from 
shunt implantation (90,91,98,99). 
 
That there is an association between age, comorbid illnesses, and response to shunt 
surgery in iNPH underscores the fact that careful patient selection based on overall 
fitness and ability to tolerate surgery is still crucial to obtaining good outcomes. The 
presence of improvement in at least one symptom in all of our patients, however, 
indicates that CSF diversion via surgical implantation of a shunt can provide some relief 
from the symptoms of iNPH even in otherwise significantly ill patients.  
 
Limitations 
Limitations of this study include retrospective design, absence of the application of 
clinical grading scale against which to directly compare PROs in the evaluation of our 
subjects, and small sample size. 
 
Conclusion 
Using patient-reported outcomes to assess patients having undergone shunt surgery for 
the treatment of iNPH leads to the reporting of similar rates of improvement when 
compared to historical data obtained through the application of clinical scales. Further 
study is needed to investigate whether or not PROs lead to higher rates of reported 
improvement relative to clinical scales, and to elucidate what factors contribute to a 
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patient’s perception of their own improvement. Until a consensus metric for evaluating 
outcomes in iNPH is established, however, PROs should be considered a viable method 




Appendix 1 – Evidentiary Table 
Study Study 
Population 







33 patients with 
iNPH, 10 with 
secondary NPH 
Progressive Dementia 




pressure, absence of 
obstructive etiology 
-Stein-Langfitt: Patients 
rated on a scale from 0 – 
IV based on overall 
symptom severity (0 = no 
symptoms, IV = full 
custodial care necessary) 
Significant 
improvement 
defined as at least 
one point increase 
in Stein-Langfitt 




24% of patients with 
INPH showed significant 
improvement  
Black (1980) 62 patients with 
iNPH 
Variable, with 
minimum criteria of 
ventriculomegaly, 




-Black: Patient outcome 
scored from “Poor” to 
“Excellent” based on 
combination of functional 





Fair, or Transient 
outcome on Black 
Scale or: one point 
increase in Stein-
Langfitt score 
9 weeks to 75 
months, mean 
36.5 months 
46.8% improved by Black 






23 patients with 
iNPH 
1) Gait disturbances or 
dementia; 2) Imaging 
confirmed 
ventriculomegaly; 3) a 
mean intraventricular 
pressure or a lumbar 
pressure <20 cm H2O; 
4) no identifiable cause 
for hydrocephalus; 5) 
the ability to walk 
within one year before 
the intracranial pressure 
monitoring; 6) the 
presence of intracranial 
pressure waves with an 
amplitude >9 mm Hg 
Gait assessed by 
equations requiring 
number of steps, time 
required, and whether or 
not assistance is required 
to walk 10m. Cognition 
assessed using a battery of 
psychometric tests 









based on an 
equation 
comparing pre- and 
post-procedure 




defined as great or 





91% of patients continued 
to show improvement in 







Krauss, et al. 
(1996) 





improvement of gait 
disturbances with CSF 
removal 
Gait, cognitive, and 
urinary symptoms scored 
from 0-3 (0 = no 
symptoms, 3 = severe 
symptoms). Improvement 
in each symptom  
following shunting scored 
from 0-2 (0 = no 
improvement, 2 = 
significant improvement) 
-Krauss Improvement 
Index (KII): (sum of 
improvement scores)/2n, 
where “n” is the number 
of cardinal symptoms 
manifest at presentation 
Shunt response was 
defined as a KII > 





90% of patients with gait 
disturbance, 88% of 
patients with cognitive 
impairment, and 76% of 
patients with urinary 
symptoms showed 
improvement at last 
follow-up. 
Boon, et al. 
(1998) 
85 patients with 




effecting both legs, 
mild to moderate 
cognitive impairment 
without aphasia, mRS 




NPH scale (sum of 
dementia and gait scales), 
Modified Mini Mental 




excellent based on 
% improvement in 
NPH score or 
improvement in 
mRS 
1, 3, 6, 9, and 
12 months 
74% of patients implanted 
with low-pressure shunts, 
and 53% of patients 
implanted with medium 
high-pressure shunts 
showed some 
improvement, with the 
mRS definition providing 
more statistically 
significant findings 
Malm, et al. 
(2000) 







MMSE, Barthel Index, 
video recording of 
ambulation 
Response to 
shunting defined as 
MMSE score 
greater than or 
equal to 25 or an 
increase of at least 
two points in 
MMSE score or 
3, 9, 18, and 
36 months 
Mental status and gait 
responded to shunting in 
69% and 67.5% of 
patients at 3 months, and 
28% and 26% at 36 
months, respectively. 75% 
of patients were living 








defined as Barthel 
Index > 65 
months, versus 28 % at 36 
months. 




presence of full clinical 
triad of gait 
disturbances, cognitive 
impairment, and urinary 
incontinence 
iNPH grading scale 
established by the 
Research Committee on 
Intractable Hydrocephalus 
(Japan) – calculated from 
sum score from 0-4 for 
each cardinal symptom (0 
= no symptoms, 4 = worst 
symptoms) 
Response to 
shunting defined as 
improvement by at 
least on point on 
iNPH scale 
3 and 36 
months 
80% of patients showed 
improvement at 3 months, 
and 73.3% had sustained 
improvement at 36 
months. Gait symptoms 
were more likely to 
improve than dementia or 
urinary symptoms (79.2% 
v. 20.8%, respectively, at 
3 months) 
Kiefer, et al. 
(2002) 
91 patients with 
iNPH 
Variable; based on 
clinical presentation 
and CSF dynamic 
parameters 
-Kiefer Index (KI): gait, 
cognitive, and urinary 
symptoms scored from 0-
6, headache from 0-4, and 
dizziness from 0-2. Scores 
summed to provide Kiefer 
index (high = more 
symptomatic disease) 
-Recovery Index (RI): 









-Good response (RI 
5-7) 
-Very good 
response (RI > 7) 





>65% of patients had 
good or very good 
recovery at last follow-up. 
88% of patients were 
shunt responders. 
Poca, et al. 
(2004) 











iNPH scale calculated 
from sum of score from 1-
5 for each cardinal 
symptom (1 = severe 
symptoms, 5 = no 
symptoms). Stein-
Langfitt. Activities of 











6 months 86% of patients showed 




rates of 85%, 86%, and 
40%, respectively. 
Neuropsychological 
testing and MMSE did not 
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on Cognitive Decline in 
the Elderly 
two or more points 
on NPH scale) 
show statistically 
significant difference pre- 
and post- procedure.  
Poca, et al. 
(2005) 





Same as Poca, et 
al.(2004), plus age > 
65, symptom duration > 
12 months, cortical 
atrophy, and MMSE < 
24  





one point on scale) 
-Moderate 
(improvement of 
two or more points 
on scale)  
 






rates of 92%, 92%, and 
33%, respectively. 
Neuropsychological 
testing and MMSE did not 
show statistically 
significant difference pre- 
and post- procedure. 






least two of the 
symptoms of gait 
disturbance, cognitive 
deficit, or urinary 
incontinence, no 
obvious etiology of 
their hydrocephalus, A- 
or B-waves on 
continuous CSF 
pressure monitoring, 
and improvement with 
3-day lumbar drain trial 
MMSE, patient or care 











improved with > 3 
point increase in 
MMSE. Response 
to shunting scored 
as improvement in 
at least one 
symptom. 






up of 18 
months. 
75% of patients showed 
improvement in at least 
one symptom and 46% 
had improvement in all of 
their symptoms at the 
study’s conclusion. Gait 
disturbance was the most 
likely symptom to 
improve 
Eide, et al. 
(2006) 
39 patients with 
iNPH 
Not specified iNPH scale calculated 
from sum of score from 1-
5 for each cardinal 
symptom (1 = severe 




(> 5 point 
improvement on 
12 months 69% of patients showed 
some improvement at 12 
months. 31% showed very 
significant improvement, 
and 15% showed 
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symptoms). iNPH scale) 
-Significant (3-4 
point improvement 




on iNPH scale) 
-Non-responders 
significant improvement. 
Kahlon, et al. 
(2007) 
46 patients with 




least one of symptoms 
of gait disturbance, 
cognitive impairment, 
or urinary incontinence, 
and either positive 
lumbar infusion test of 
CSF tap test 
Walk time, step number 
reaction time, memory, 
identical forms tests, and 
Barthel index 
Authors report % 
change in scores of 
pre- and post-
operative tests 
6 months (all 
patients) and 
5 years (23 
patients) 
More than 80% of 
patients showed objective 
improvement and 96% 
reported subjective 
improvement at six 
months. 43% of patients 
showed some objective 
improvement and 56% 
reported subjective 
improvement at 5 years 
Kubo, et al. 
(2007) 
38 patient with 
iNPH evaluated 
to validate new 
iNPH scale. 14 
eventually 
shunted. 
Age > 60 years, at least 
one of the symptoms of 
gait disturbance, 
cognitive impairment, 
or urinary incontinence, 
imaging confirmed 
ventriculomegaly, 




pressure on lumbar 
puncture. Decision to 
shunt based on 
individual surgeon’s 
opinion. 
iNPH grading scale 
calculated as sum of score 
from 0-4 for each cardinal 
symptom (0 = no 
symptoms, 4 = worst 
symptoms). MMSE, 
Frontal Assessment 




Questionnaire – Short 
Form 
Quantified change 
in iNPH scale 
presented in results 
1 to 12 
months 
79% of shunted patients 
showed at least one point 
of improvement on the 
iNPH grading scale 
Pujari, et al. 
(2008) 
55 patients with 
iNPH 
See: McGirt (2005) MMSE, Tinetti gait score, 
patient or care provider 
See: McGirt (2005) 1, 3, and 6 
months, with 
71% of patients reported 
improvement in all 
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symptoms at 3 years 
following shunt surgery. 
80% of patients still 
followed at 7 years 
continued to report 
improvement of all 
symptoms relative to pre-
surgical baseline. 
Kiefer, et al. 
(2010) 




Presentation with at 
least two of the 
symptoms of gait 
disturbance, cognitive 




-Kiefer Index (KI) 
-Recover Index (RI) 
-Comorbidity Index 
(CMI): between 1-3 
points assigned for 
comorbidities in each of 






disease, and other 
neurologic disease 
Response to 
shunting defined at 








iNPH patients with CMI 
0-3 had >80% response 
rate. When controlled for 
age and CMI, there was 
no statistically significant 
difference in the response 
rate between iNPH and 
non-iNPH. Patients with 
iNPH were ten-fold more 
likely to have an older age 
and a higher CMI at 
presentation than patients 
with non-iNPH. 
Mirzayan, et al. 
(2010) 
51 patients with 
iNPH 




flattening of the 
parasagittal, 
frontoparietal sulci, and 
improvement of gait 
with CSF drainage 
Krauss Improvement 
Index 












Average long-term KII 
for gait, cognitive, and 
urinary symptoms were 







Age between 60 and 85, 
at least one of the 
symptoms of gait 
disturbance, cognitive 
mRS, Kubo’s iNPH 
grading scale, Timed up-
and-go, MMSE 
Response to 
shunting defined as 
at least one point of 
improvement on 
12 months 80% of patients 
responded to shunting 
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absence of known 
etiology of 
hydrocephalus, and 
opening pressure < 
20cm H2O on LP 
mRS at one year 
Tisell, et al. 
(2011) 






“symptoms and signs of 
iNPH”, and Wahlund 
score 2 or 3 white 
matter changes 
Seven psychometric tests 
(Bingley, Identical Forms, 
Reaction Time, Grooved 
Pegboard, RAVLT, 
Tracks, Stroop Color 
Naming) and six motor 
tasks (time to sit upright 
from lying down, time to 
walk 10 m, time to climb 
up and down six stairs, 
no. of steps to turn 180, 




as change in mean 
of motor and 
psychometric tests 
3 and 6 
months 
22% overall improvement 
in aggregate average 
scores for all 14 patients 
at 6 months 








onset of gait 
disturbance effecting 
tandem walk, turning, 
and stride length; 2) 
mild to moderate 
(MMSE score greater 
than or equal to 21) 
cognitive impairment 
presenting together with 
or after presentation of 
gait symptoms; 3) MRI 
mRS,  
-Hellstrom’s iNPH scale: 
The domains of gait 
impairment, cognitive 
ability, balance, and 
urinary incontinence are 
each given a score from 
0-100 based on a 
combination of ordinal 
clinical scales or objective 
tests unique to each 
symptom. The iNPH 




shunting defined as 
improvement in 
mRS of at least one 
point  or 
improvement of at 
least 5 points on 
Hellstrom’s iNPH 
scale 
12 months 64% and 84% of patients 
were improved at one 
year by mRS and 
Hellstrom’s iNPH scale 
criteria, respectively. 82% 
of patients were living 
independently at one year 






enlargement with little 






apraxia, or agnosia, or 
MMSE score < 21; 3) 
MRI with 
ventriculomegaly and 
cortical atrophy, also 
including either mild to 
severe leucoaraiosis or 
single area of infarct 
nce)+(urinary)]/5(or total 
number of scores 
available) 
Andren, et al. 
(2014) 
33 patients with 
iNPH waiting 





and 69 patients 
waiting no 






“probable” iNPH as per 
criteria set forth in most 
recent international 
guidelines (10) 
Hellstrom’s iNPH scale Improvement of at 
least 5 points on 
Hellostrom’s iNPH 
scale 
3 months Significant improvement 
following shunting was 
demonstrated in all 
symptoms domains in 
each group. There was a 
significant difference in 
the degree of 
improvement between the 
delayed shunting cohort 
and the early shunting 
cohort, with the early 
shunting cohort having a 
greater degree of 
improvement in all 
domains except for 
incontinence and MMSE, 
for which there was no 
significant difference 
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